Global Cholera Vaccine Supply Reaches Critical Level, Enabling Resumption of Life-Saving Preventive Campaigns

For the first time in over three years, the global supply of oral cholera vaccines (OCV) has reached a sufficient level to allow for the crucial resumption of life-saving preventive campaigns. This pivotal announcement was made jointly by Gavi, the Vaccine Alliance, UNICEF, and the World Health Organization (WHO), marking a significant turning point in the ongoing battle against a disease that has seen a dramatic resurgence worldwide. Mozambique has emerged as the pioneering nation to restart these vital preventive vaccinations, a move that comes after a challenging period where global surges in cholera cases overwhelmed demand and led to severe shortages of OCV stocks, forcing a reactive rather than proactive approach to outbreaks.

The Unprecedented Global Cholera Crisis

The world has witnessed a relentless and alarming surge in cholera cases since 2021, with numerous countries grappling with severe outbreaks. This crisis has been exacerbated by a confluence of factors including climate change-induced extreme weather events like floods and droughts, protracted conflicts, mass displacements of populations, and chronically underdeveloped or damaged water, sanitation, and hygiene (WASH) infrastructure. These conditions create fertile ground for the rapid spread of cholera, a highly contagious bacterial infection that causes severe acute watery diarrhea and can lead to death within hours if left untreated.

In 2023 alone, more than 600,000 cases of cholera or acute watery diarrhoea and nearly 7,600 deaths were reported to the WHO from 33 countries. However, these figures are widely considered to be significant underestimates due to challenges in surveillance and reporting in many affected regions. The true burden of the disease is likely far greater. Countries like Haiti, Syria, Ethiopia, Malawi, and Yemen have been particularly hard-hit, facing immense humanitarian challenges alongside the public health crisis. The scale of the outbreaks compelled international health bodies to temporarily pivot from a two-dose vaccination strategy to a single-dose approach in late 2022, a desperate measure to stretch the limited vaccine supply and protect as many people as possible, even if for a shorter duration. This reactive stance, while necessary, highlighted the dire need for a more robust and readily available vaccine supply to enable preventive action.

A New Chapter: Resuming Prevention in Mozambique

The decision to resume preventive campaigns signifies a strategic shift from merely containing outbreaks to actively preventing them. Mozambique’s immediate restart of preventive vaccination is particularly critical given its current predicament. The nation is not only battling an ongoing cholera outbreak but is also recovering from devastating floods that have affected over 700,000 people and displaced a significant portion of its population. Such natural disasters invariably disrupt essential health systems and severely damage water infrastructure, creating ideal conditions for waterborne diseases like cholera to thrive and spread unchecked.

Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, underscored the gravity of the situation and the importance of this breakthrough. "Global vaccine shortages forced us into a cycle of reacting to cholera outbreaks instead of preventing them. We are now in a stronger position to break that cycle," he stated. Dr. Tedros extended gratitude to EUBiologics, currently the sole manufacturer producing cholera vaccines at the scale required for mass vaccination campaigns, acknowledging their efforts and issuing a global call for other manufacturers to enter this vital space. "These vaccines will save lives," he emphasized, highlighting the immediate and tangible impact of the increased supply.

The Mechanics of a Major Supply Boost

The dramatic increase in global OCV supply, doubling from 35 million doses in 2022 to a projected nearly 70 million doses by 2025, is the result of years of sustained, collaborative efforts among global health agencies, manufacturers, and partners. This concerted drive aimed to meet the escalating demand for outbreak response, expand production capacity, and streamline the allocation process to ensure that even limited supplies reached the most critical areas. Gavi, the Vaccine Alliance, plays a crucial role in financing these doses, while UNICEF is responsible for their procurement and delivery to countries.

The initial allocation of 20 million doses for preventive campaigns is a testament to this collaborative success. Mozambique received 3.6 million doses, while the Democratic Republic of the Congo (DRC), also experiencing significant outbreaks, was allocated 6.1 million doses. An additional 10.3 million doses are planned for delivery to Bangladesh. These three countries were strategically selected based on stringent allocation criteria established by the Global Task Force for Cholera Control (GTFCC). The GTFCC, a partnership comprising over 50 organizations, ensures that cholera vaccines for preventive campaigns are distributed systematically, equitably, and transparently, prioritizing areas with the highest risk and greatest public health impact.

Dr. Sania Nishtar, CEO of Gavi, the Vaccine Alliance, reflected on the lessons learned from the recent crisis. "The multi-year surge in cholera cases and resulting unprecedented demand for vaccines were stark reminders that sustainable, accessible vaccine supply is a global public good – and the world cannot afford complacency," she remarked. Dr. Nishtar expressed profound gratitude to partners and manufacturers, particularly EUBiologics, for their collaboration, and to Gavi’s donors whose unwavering support finances the global OCV stockpile and enables both outbreak response and preventive campaigns.

A Holistic Approach: Beyond Vaccination

While the availability of vaccines is a monumental step forward, global health leaders consistently emphasize that vaccination is but one component of a comprehensive strategy to combat cholera. Catherine Russell, UNICEF Executive Director, articulated this crucial point: "For the first time in years, this increase in vaccines will allow us to better prevent large-scale cholera emergencies. Resuming preventive cholera vaccination will protect children and help stop this highly contagious disease in its tracks. But it must go hand in hand with other efforts, including better access to safe water and basic sanitation."

Indeed, long-term investments in robust water, sanitation, and hygiene (WASH) infrastructure remain absolutely essential. These foundational elements are critical to preventing outbreaks from starting and spreading, and for achieving sustainable reductions in cholera-related deaths. Complementary efforts include strengthening disease surveillance systems for early detection, ensuring rapid access to treatment, and fostering robust community engagement to promote hygiene practices and early care-seeking. Dr. Ilesh Jani, Chair of the Steering Committee of the GTFCC, reinforced this sentiment, stating, "This milestone shows the power of bringing together diverse partners to build a more reliable response to cholera. Preventive vaccination helps shield communities and buys critical time. However, lasting progress will depend on long-term investment in infrastructure, for which political commitment is indispensable."

The oral cholera vaccine itself is both safe and highly effective, recommended for individuals over one year of age. A single dose provides short-term protection for at least six months and can be instrumental in bringing outbreaks under control. For longer-term immunity, two doses offer protection against infection for approximately three years. While global vaccine supply is steadily improving, the one-dose strategy will, for the time being, remain the standard for outbreak responses, with the use of two doses considered on a case-by-case basis depending on local epidemiological contexts and supply availability.

Chronology of a Crisis and a Turning Point

• 2021: Global cholera cases begin a rapid and alarming surge, driven by conflicts, climate change, and weak infrastructure, marking the beginning of an unprecedented multi-year crisis.
• October 2022: Due to soaring demand and critical shortages, the Global Task Force for Cholera Control (GTFCC) announces a temporary shift from a two-dose to a single-dose vaccination strategy to conserve limited supplies and reach more people during outbreaks. Global supply stands at approximately 35 million doses.
• 2023: Cholera outbreaks continue to escalate across multiple continents, leading to over 600,000 reported cases and nearly 7,600 deaths. Efforts intensify among global health partners and manufacturers to increase OCV production capacity.
• Late 2024 / Early 2025 (Projected): Sustained collaborative efforts begin to yield results, with global OCV supply increasing significantly.
• Current Announcement: Gavi, UNICEF, and WHO announce that OCV supply has reached a level sufficient to resume preventive vaccination campaigns, a first in over three years.
• Immediate Action: Mozambique becomes the first country to restart preventive vaccination campaigns, deploying 3.6 million doses amid an ongoing outbreak and flood aftermath.
• Initial Allocations: A first allocation of 20 million doses is deployed for preventive campaigns, with 6.1 million doses destined for the Democratic Republic of the Congo and 10.3 million doses planned for Bangladesh.
• Future Outlook (by 2025): Annual global OCV supply is projected to nearly double to 70 million doses, strengthening the world’s ability to respond to and prevent cholera.

Implications and Future Outlook

The resumption of preventive cholera vaccination campaigns holds profound implications for global health security and the well-being of vulnerable communities. It represents a critical step towards reversing the alarming trend of increasing cholera cases and deaths. By shifting from a reactive stance to a proactive one, international efforts can significantly reduce mortality and morbidity, particularly among children who are disproportionately affected by the disease.

The lessons learned from this period of severe vaccine shortage underscore the vital importance of diversifying vaccine manufacturing, investing in robust supply chains, and establishing sustainable funding mechanisms for global stockpiles. While the current increase in supply is commendable, the call for other manufacturers to enter the OCV space highlights the ongoing need for greater resilience and redundancy in vaccine production to prevent future shortages.

However, the fight against cholera is far from over. The underlying drivers of the disease – climate change, persistent conflicts, rapid urbanization without adequate infrastructure, and entrenched poverty – continue to pose significant challenges. Sustained political commitment and long-term financial investment in fundamental public health infrastructure, particularly safe water and sanitation systems, will be indispensable for achieving lasting progress. The current breakthrough provides a window of opportunity to implement comprehensive strategies, combining the power of vaccination with essential WASH interventions, robust surveillance, and accessible treatment, to move towards a world free from the devastating impact of cholera.

About Gavi, the Vaccine Alliance

Gavi, the Vaccine Alliance is a public-private partnership dedicated to vaccinating more than half of the world’s children against some of the deadliest diseases. Bringing together developing country and donor governments, the World Health Organization, UNICEF, the World Bank, the vaccine industry, technical agencies, civil society, the Gates Foundation, and other private sector partners, Gavi has helped immunize over 1.2 billion children since its inception in 2000. This effort has prevented more than 20.6 million future deaths, contributing to a halving of child mortality in 78 lower-income countries. Gavi also plays a critical role in global health security by supporting health systems and funding global stockpiles for vaccines against diseases like Ebola, cholera, meningococcal disease, and yellow fever.

About UNICEF

UNICEF, the United Nations agency for children, is committed to protecting the rights of every child, everywhere. Working in over 190 countries and territories, UNICEF strives to help the most disadvantaged children survive, thrive, and fulfill their potential. Their work encompasses a wide range of interventions, from providing access to safe water and sanitation to delivering life-saving vaccines and promoting education.

About WHO

The World Health Organization (WHO) is the UN agency for health, dedicated to the well-being of all people and guided by scientific principles. Leading and championing global efforts, WHO aims to give everyone, everywhere, an equal chance at a safe and healthy life. Operating in more than 150 locations, WHO spearheads responses to health emergencies, works to prevent disease, addresses the root causes of health issues, and expands access to medicines and healthcare. Its core mission is to promote health, keep the world safe, and serve the vulnerable populations globally.